ArticleAnatolian journal of cardiology2026
Study of the Mechanism by Which Shenfu Injection Regulates Cardiomyocyte Hypertrophy Based on Dopamine Receptor D2-Mediated Mitochondrial Fission.
Article in Anatolian journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundShenfu Injection (SFI) has been widely utilized in the treatment of cardiovascular diseases in China for over 3 decades. In recent years, the therapeutic role of SFI in cardiovascular diseases has garnered significant attention. This study aims to elucidate the effects and possible mechanism of SFI using in vitro experiments and network pharmacology analysis.
methodsHypertrophy was induced by Angiotensin II (Ang II) treatment of HL-1 and isoprenaline (ISO) treatment of AC16. First, cell viability was detected upon different concentrations of SFI to screen the safe dosage of SFI. The effect of SFI on cell functions was evaluated by cell size, atrial natriuretic peptide/brain type natriuretic peptide (ANP/BNP) levels, mitochondrial morphology, and Ser616/Ser579 or Ser637/Ser600 levels. The potential targets of SFI against cardiomyocyte hypertrophy were predicted by network pharmacology, and then experimentally validated by qRT-PCR.
resultsShenfu Injection treatment significantly reduced cell size, ANP expression, BNP expression, and mitochondrial injury compared to Ang and ISO groups (P < .001). Western blot analysis showed that SFI decreased the expression of Dynamin-related protein 1 (Drp1) phosphorylation at Ser616/Ser579 and increased the expression of Drp1 phosphorylation at Ser637/Ser600 in Ang- and ISO-induced cells. Network pharmacology analysis and cell experiments showed SFI decreased dopamine receptor D2 (DRD2) and increased protein kinase A levels in induced cardiomyocytes.
conclusionIn summary, the findings demonstrate that SFI may alleviate cardiomyocyte hypertrophy by targeting DRD2 and inhibiting mitochondrial fission. #Yuhan Zhang and Su Zhang contributed equally to this work.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.